APRE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Aprea provided an update on the ACESOT-1051 program, accelerating enrollment for the WEE1 inhibitor APR-1051 with clinical data expected in Q4 2026Jul 31, 2026
- Aprea Therapeutics reported additional positive clinical activity for the WEE1 inhibitor APR-1051, including a second partial response in the ongoing ACESOT-1051 trialFeb 18, 2026
- Aprea Therapeutics strengthened its global patent portfolio in DNA damage response cancer therapies to support pipeline expansionFeb 12, 2026
- Aprea Therapeutics reported early clinical proof-of-concept for WEE1 inhibitor APR-1051Jan 30, 2026
- Aprea Therapeutics provides clinical update from ACESOT-1051 trial showing early signals of activity for WEE1 kinase inhibitor APR-1051Oct 24, 2025